00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
00:28 , May 24, 2019 |  BC Innovations  |  Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
14:21 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

WWP1 inhibitor for MYC-driven prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer In vitro and mouse studies identified a WWP1 inhibitor that could help treat MYC-driven prostate cancer. In a mouse model of MYC-overexpressing prostate cancer, systemic knockout of WWP1 or...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
13:54 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Cell-penetrating mini-protein targeting MYC for lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Cell culture and mouse studies suggest a cell-penetrating mini-protein targeting MYC-MYC and MYC-MAX interactions could help treat lung cancer. In three human non-small cell lung cancer (NSCLC) cell lines,...
21:47 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

MAX homodimer stabilizer for MYC-driven cancers

DISEASE CATEGORY: Cancer INDICATION: Hematologic malignancies; liver cancer; lung cancer; prostate cancer; pancreatic cancer Cell culture and mouse studies identified a MAX homodimer stabilizer that could help treat MYC-driven ALL, lung, liver and other cancers....
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
18:48 , Mar 20, 2019 |  BC Extra  |  Preclinical News

Peptomyc study details MYC-targeted cell-penetrating biologic

A new study from Peptomyc provides the latest evidence that cell-penetrating biologics can hit the previously intractable cancer target MYC. In a Science Translational Medicine paper, the company showed its mini-protein targeting MYC can reach...
20:13 , Mar 18, 2019 |  BC Extra  |  Preclinical News

Kronos co-founder, MIT team discover compound that indirectly blocks MYC

An MIT team led by Kronos co-founder Angela Koehler has discovered a small molecule that prevents MYC, an oncogene considered undruggable, from driving gene expression by locking up its binding partner MAX. The transcription factor...